Learn how analytical methodologies can be used to identify RSV pre- and post-fusion proteins for vaccine development.

Scanning electron micrograph of human respiratory syncytial virus (RSV) virions (colorized blue) and labeled with anti-RSV F protein/gold ... Sales of both GSK’s and Pfizer’s vaccines for ...

Revenue for Arexvy and Abrysvo fell sharply year over year in the fourth quarter due to narrower U.S. guidelines for their ...

The respiratory syncytial virus (RSV) vaccine produced strong immune responses in older adults during its first two seasons of use, according to a new study.

Pfizer expects $1B hit from IRA's Part D redesign and no major M&A in 2025 RSV vaccine Abrysvo specifically floundered in the fourth quarter. The product's sales fell 62% year over year to $198 ...

Pfizer is looking to follow its vaccine ... comparison with placebo in older people at risk of RSV infections. The US Centres for Disease Control and Prevention (CDC) estimates that around 177,000 ...

Robust immune responses were observed among healthy and high-risk younger adults who received the Ad26/protein RSV preF vaccine.

What are the lasting impacts of RSV, and how can you prevent your infant from getting the infection? Dr. Stephania Cormier is ...

Pfizer has bolstered the evidence behind its respiratory syncytial virus (RSV) vaccine with a positive trial of the shot used to protect newborns, adding to earlier results in older adults. The ...

Vincenza Snow, MD, Senior Director, Pfizer Medical Affairs joined us to talk about RSV today. RSV (respiratory syncytial virus) is a highly contagious respiratory virus, meaning it can spread ...